Podcast 14 Jun 2024Looking to cure type 1 diabetes with precision medicine Listen to our conversation with Diamyd Medical, working on precision medicine therapies for the prevention and treatment of type 1 diabetes. June 14, 2024 Share WhatsApp Twitter Linkedin Email Listen Now Apple Music Spotify More
In Depth 18 Jan 2024 GLP-1 agonists: what’s the hype about? GLP-1 agonists have been on the radar for a while to treat diabetes and obesity. And of late, there has been renewed interest in these drugs. January 18, 2024 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 4 Jan 2024 Can GLP-1 agonists, the miraculous obesity drugs, treat cardiovascular diseases? Discover how GLP-1 agonists, known for treating diabetes and obesity, are now being studied for their potential in tackling heart diseases. January 4, 2024 - 6 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 21 Nov 2023 Beyond insulin: six cutting-edge diabetes biotech companies you should know about As we predicted last year, the diabetes market is booming, particularly after the incredible success of new diabetes drugs like Novo Nordisk’s Ozempic and Eli Lilly’s Mounjaro. There are now several diabetes biotech companies that are garnering attention, all with their own innovative solutions to tackling both type 1 and type 2 diabetes. The prevalence […] November 21, 2023 - 7 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 26 Jul 2023 Diabetes drug could promote healthy aging A research team from the School of Public Health, LKS Faculty of Medicine of the University of Hong Kong (HKUMed), has provided genetic evidence that metformin might promote healthy aging using a cohort study of more than 300,000 participants of European descent (UK Biobank). The proof-of-concept work supports further clinical research into the drug repositioning […] July 26, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jun 2023 FDA approves type 2 diabetes drug for children 10 and older The U.S. Food and Drug Administration (FDA) has approved Jardiance (empagliflozin) 10 mg and 25 mg tablets to lower blood sugar along with diet and exercise in children 10 years and older with type 2 diabetes, Boehringer Ingelheim and Eli Lilly and Company have announced. “As the burden of type 2 diabetes increases among young […] June 22, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jun 2023 Quell in potential $2B AstraZeneca cell therapy deal Quell Therapeutics Ltd, a developer of engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, has entered into a collaboration, exclusive option and license agreement with AstraZeneca to develop, manufacture and commercialize autologous, engineered Treg cell therapies for two autoimmune disease indications. “We are extremely pleased to have AstraZeneca on […] June 9, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 30 May 2023 Researchers identify gene expression signature to predict progression of type 1 diabetes Researchers from Turku Bioscience Centre and InFLAMES Flagship at the University of Turku in Finland, have identified a gene expression signature that can predict the progression of type 1 diabetes.The study, led by Laura Elo and Riitta Lahesmaa, aimed to identify transcriptional changes associated with disease progression in patients with recent-onset type 1 diabetes. The […] May 30, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 May 2023 DiogenX raises €27.5M for “breakthrough” diabetes treatment DiogenX, a biotech company focused on regenerating insulin-producing beta cells for the treatment of diabetes, has announced the successful completion of a €27.5 million ($30 million) Series A financing round. New investors Roche Venture Fund, Eli Lilly and Company and Omnes joined this round alongside existing investors Boehringer Ingelheim Venture Fund (BIVF), JDRF T1D Fund, […] May 12, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 13 Apr 2023 Aspect and Novo Nordisk working on bioprinted tissue for diabetes and obesity Aspect Biosystems and Novo Nordisk A/S are set to collaborate on developing bioprinted tissue therapeutics to replace, repair, or supplement biological functions inside the body with the aim of delivering a new class of disease-modifying treatments for diabetes and obesity. The collaboration will leverage Aspect’s bioprinting technology and Novo Nordisk’s background in stem cell differentiation […] April 13, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 13 Mar 2023 Sanofi adds diabetes drug through Provention Bio $2.9B acquisition Sanofi and Provention Bio, Inc., a U.S.-based, publicly traded biopharmaceutical company focused on intercepting and preventing immune-mediated diseases including type 1 diabetes (T1D), have entered into an agreement under which Sanofi has agreed to acquire Provention Bio, Inc., for $25.00 per share in cash, representing an equity value of approximately $2.9 billion. The transaction adds […] March 13, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 Mar 2023 Researchers develop treatment for vancomycin-resistant bacteria Researchers from several institutions have developed a treatment for bacteria resistant to vancomycin, which is also known as vancomycin-resistant Enterococcus faecalis (VRE). The group consists of researchers from the Antimicrobial Resistance (AMR) Interdisciplinary Research Group (IRG) at Singapore-MIT Alliance for Research and Technology (SMART), MIT’s research enterprise in Singapore, in collaboration with Singapore Centre for […] March 9, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email